Metabolomics-driven approaches for identifying therapeutic targets in drug discovery

Abstract

Identification of therapeutic targets can directly elucidate the mechanism and effect of drug therapy, which is a central step in drug development. The disconnect between protein targets and phenotypes under complex mechanisms hampers comprehensive target understanding. Metabolomics, as a systems biology tool that captures phenotypic changes induced by exogenous compounds, has emerged as a valuable approach for target identification. A comprehensive overview was provided in this review to illustrate the principles and advantages of metabolomics, delving into the application of metabolomics in target identification. This review outlines various metabolomics-based methods, such as dose–response metabolomics, stable isotope-resolved metabolomics, and multiomics, which identify key enzymes and metabolic pathways affected by exogenous substances through dose-dependent metabolite–drug interactions. Emerging techniques, including single-cell metabolomics, artificial intelligence, and mass spectrometry imaging, are also explored for their potential to enhance target discovery. The review emphasizes metabolomics’ critical role in advancing our understanding of disease mechanisms and accelerating targeted drug development, while acknowledging current challenges in the field.

Keywords

artificial intelligence / drug development / metabolomics / single-cell metabolomics / target identification

References

[1] Imming P, Sinning C, Meyer A. Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006; 5(1): 821-834.

[2] Zhou Y, Zhang Y, Lian X, et al. Therapeutic target database update 2022: facilitating drug discovery with enriched comparative data of targeted agents. Nucleic Acids Res. 2022; 50: D1398-D1407. D1.

[3] DiNardo CD, Stein EM, de Botton S, et al. Durable remissions with ivosidenib in IDH1-mutated relapsed or refractory AML. New Engl J Med. 2018; 378(25): 2386-2398.

[4] Zhang Y, Han C, Zhu W, et al. Glucagon potentiates insulin secretion via beta-cell GCGR at physiological concentrations of glucose. Cells. 2021; 10(9): 2495.

[5] Harding MW, Galat A, Uehling DE, Schreiber SL. A receptor for the immuno-suppressant FK506 is a cis–trans peptidyl-prolyl isomerase. Nature. 1989; 341(6244): 758-760.

[6] Brown EJ, Albers MW, Shin TB, et al. A mammalian protein targeted by G1-arresting rapamycin-receptor complex. Nature. 1994; 369(6483): 756-758.

[7] Lin Z, Amako Y, Kabir F, Flaxman HA, Budnik B, Woo CM. Development of photolenalidomide for cellular target identification. J Am Chem Soc. 2022; 144(1): 606-614.

[8] Park K, Cho AE. Using reverse docking to identify potential targets for ginsenosides. J Ginseng Res. 2017; 41(4): 534-539.

[9] Udrea A-M, Dinache A, Staicu A, Avram S. Target prediction of 5, 10, 15, 20-tetrakis(4’-sulfonatophenyl)-porphyrin using molecular docking. Pharmaceutics. 2022; 14(11): 2390.

[10] Li Y, Hou G, Zhou H, et al. Multi-platform omics analysis reveals molecular signature for COVID-19 pathogenesis, prognosis and drug target discovery. Signal Transduct Tar. 2021; 6(1): 155.

[11] Schmuck MR, Temme T, Dach K, et al. Omnisphero: a high-content image analysis (HCA) approach for phenotypic developmental neurotoxicity (DNT) screenings of organoid neurosphere cultures in vitro. Arch Toxicol. 2017; 91(4): 2017-2028.

[12] Dragunow M. High-content analysis in neuroscience. Nat Rev Neurosci. 2008; 9(10): 779-788.

[13] Pierozan P, Kosnik M, Karlsson O. High-content analysis shows synergistic effects of low perfluorooctanoic acid (PFOS) and perfluorooctane sulfonic acid (PFOA) mixture concentrations on human breast epithelial cell carcinogenesis. Environ Int. 2023; 172: 107746.

[14] Li J, Chi J, Yang Y, et al. PHDs-seq: a large-scale phenotypic screening method for drug discovery through parallel multi-readout quantification. Cell Regen. 2023; 12(1): 22.

[15] Vincent F, Nueda A, Lee J, Schenone M, Prunotto M, Mercola M. Phenotypic drug discovery: recent successes, lessons learned and new directions. Nat Rev Drug Discov. 2022; 21(12): 899-914.

[16] Robinson AB, Robinson NE. Origins of metabolic profiling. In: Metz TO, ed. Metabolic Profiling: Methods and Protocols. Humana Press; 2011: 1-23. In. ed.

[17] Pauling L, Robinson AB, Teranishi R, Cary P. Quantitative analysis of urine vapor and breath by gas-liquid partition chromatography. Proc Natl Acad Sci USA. 1971; 68(10): 2374-2376.

[18] Astarita G, Kelly RS, Lasky-Su J. Metabolomics and lipidomics strategies in modern drug discovery and development. Drug Discov Today. 2023; 28(10): 103751.

[19] Wishart DS. Emerging applications of metabolomics in drug discovery and precision medicine. Nat Rev Drug Discov. 2016; 15(7): 473-484.

[20] Frederich M, Pirotte B, Fillet M, de Tullio P. Metabolomics as a challenging approach for medicinal chemistry and personalized medicine. J Med Chem. 2016; 59(19): 8649-8666.

[21] Shi T, Zhu A, Jia J, et al. Metabolomics analysis and metabolite-agronomic trait associations using kernels of wheat (Triticum aestivum) recombinant inbred lines. Plant J. 2020; 103(1): 279-292.

[22] Wishart DS. Metabolomics: applications to food science and nutrition research. Trends Food Sci Technol. 2008; 19(9): 482-493.

[23] Pang H, Hu Z. Metabolomics in drug research and development: the recent advances in technologies and applications. Acta Pharm Sin B. 2023; 13(8): 3238-3251.

[24] Hu L, Liu J, Zhang W, et al. Functional metabolomics decipher biochemical functions and associated mechanisms underlie small-molecule metabolism. Mass Spectrom Rev. 2020; 39(5-6): 417-433.

[25] Alarcon-Barrera JC, Kostidis S, Ondo-Mendez A, Giera M. Recent advances in metabolomics analysis for early drug development. Drug Discov Today. 2022; 27(6): 1763-1773.

[26] Danzi F, Pacchiana R, Mafficini A, et al. To metabolomics and beyond: a technological portfolio to investigate cancer metabolism. Signal Transduct Tar. 2023; 8(1): 137.

[27] Johnson CH, Ivanisevic J, Siuzdak G. Metabolomics beyond biomarkers and towards mechanisms. Nat Rev Mol Cell Biol. 2016; 17: 451-459.

[28] Paananen J, Fortino V. An omics perspective on drug target discovery platforms. Brief Bioinform. 2020; 21(6): 1937-1953.

[29] Bakheet TM, Doig AJ. Properties and identification of human protein drug targets. Bioinformatics. 2009; 25(4): 451-457.

[30] Peng B, Li H, Peng X-X. Functional metabolomics: from biomarker discovery to metabolome reprogramming. Protein Cell. 2015; 6(9): 628-637.

[31] Piazza I, Kochanowski K, Cappelletti V, et al. A map of protein-metabolite interactions reveals principles of chemical communication. Cell. 2018; 172(1-2): 358-372.

[32] Fogel DB. Factors associated with clinical trials that fail and opportunities for improving the likelihood of success: a review. Cont Clin Trial Comm. 2018; 11: 156-164.

[33] Ramsay RR, Popovic-Nikolic MR, Nikolic K, Uliassi E, Bolognesi ML. A perspective on multi-target drug discovery and design for complex diseases. Clin Transl Med. 2018; 7(1): 1-14.

[34] Benek O, Korabecny J, Soukup O. A perspective on multi-target drugs for Alzheimer’s disease. Trends Pharmacol Sci. 2020; 41(7): 434-445.

[35] Matthews H, Hanison J, Nirmalan N. “Omics”-informed drug and biomarker discovery: opportunities, challenges and future perspectives. Proteomes. 2016; 4(3): 28.

[36] Rinschen MM, Ivanisevic J, Giera M, Siuzdak G. Identification of bioactive metabolites using activity metabolomics. Nat Rev Mol Cell Biol. 2019; 20(6): 353-367.

[37] Abu Bakar MH, Sarmidi MR, Cheng KK, et al. Metabolomics—the complementary field in systems biology: a review on obesity and type 2 diabetes. Mol Biosyst. 2015; 11(7): 1742-1774.

[38] Wang R, Li B, Lam SM, Shui G. Integration of lipidomics and metabolomics for in-depth understanding of cellular mechanism and disease progression. J Genet Genomics. 2020; 47(2): 69-83.

[39] Zullig T, Kofeler HC. High resolution mass spectrometry in lipidomics. Mass Spectrom Rev. 2021; 40(3): 162-176.

[40] Sindelar M, Patti GJ. Chemical discovery in the era of metabolomics. J Am Chem Soc. 2020; 142(20): 9097-9105.

[41] Salek RM, Steinbeck C, Viant MR, Goodacre R, Dunn WB. The role of reporting standards for metabolite annotation and identification in metabolomic studies. GigaScience. 2013; 2(1): 13-16.

[42] Zheng F, Zhao X, Zeng Z, et al. Development of a plasma pseudotargeted metabolomics method based on ultra-high-performance liquid chromatography-mass spectrometry. Nat Protoc. 2020; 15(8): 2519-2537.

[43] Bruzzone C, Gil-Redondo R, Seco M, et al. A molecular signature for the metabolic syndrome by urine metabolomics. Cardiovasc Diabetol. 2021; 20(1): 155.

[44] Zheng J, Zhang L, Johnson M, Mandal R, Wishart DS. Comprehensive targeted metabolomic assay for urine analysis. Anal Chem. 2020; 92(15): 10627-10634.

[45] Locasale JW, Melman T, Song S, et al. Metabolomics of human cerebrospinal fluid identifies signatures of malignant glioma. Mol Cell Proteomics. 2012; 11(6): M111014688.

[46] Trezzi JP, Galozzi S, Jaeger C, et al. Distinct metabolomic signature in cerebrospinal fluid in early parkinson’s disease. Movement Disord. 2017; 32(10): 1401-1408.

[47] Chen D, Yu J, Zhang Z, Su X, Li L, Li L. Controlling preanalytical process in high-coverage quantitative metabolomics: spot-sample collection for mouse urine and fecal metabolome profiling. Anal Chem. 2019; 91(8): 4958-4963.

[48] Asai Y, Itoi T, Sofuni A, et al. Su1316 - early detection of pancreatic cancer using salivary metabolomics. Gastroenterology. 2018; 154(6):S-517-S-518.

[49] Halama A, Kulinski M, Kader SA, et al. Measurement of 1, 5-anhydroglucitol in blood and saliva: from non-targeted metabolomics to biochemical assay. J Transl Med. 2016; 14(1): 1-9.

[50] Chen P-H, Cai L, Huffman K, et al. Metabolic diversity in human non-small cell lung cancer cells. Mol Cell. 2019; 76(5): 838-851.

[51] Batista U, Garvas M, Nemec M, Schara M, Veranič P, Koklic T. Effects of different detachment procedures on viability, nitroxide reduction kinetics and plasma membrane heterogeneity of V-79 cells. Cell Biol Int. 2014; 34(6): 663-668.

[52] Artati A, Prehn C, Adamski J. LC-MS/MS-based metabolomics for cell cultures. In: Mandenius C-F, Ross JA, eds. Cell-Based Assays using iPSCs for Drug Development and Testing. 2019: 119-130. Springer.

[53] Artati A, Prehn C, Adamski J, LC-MSMS-based metabolomics for cell cultures. Methods Mol Biol. 2019; 1994: 119-130.Ross JA. Methods in Molecular Biology. 2019. Humana Press; 1994.

[54] Xiao Y, Ma D, Yang Y-S, et al. Comprehensive metabolomics expands precision medicine for triple-negative breast cancer. Cell Res. 2022; 32(5): 477-490.

[55] Saoi M, Britz-McKibbin P. New advances in tissue metabolomics: a review. Metabolites. 2021; 11(10): 672.

[56] Gong Z-G, Hu J, Wu X, Xu Y-J. The recent developments in sample preparation for mass spectrometry-based metabolomics. Crit Rev Anal Chem. 2017; 47(4): 325-331.

[57] Lepoittevin M, Blancart-Remaury Q, Kerforne T, Pellerin L, Hauet T, Thuillier R. Comparison between 5 extractions methods in either plasma or serum to determine the optimal extraction and matrix combination for human metabolomics. Cell Mol Biol Lett. 2023; 28(1): 43.

[58] Tulipani S, Llorach R, Urpi-Sarda M, Andres-Lacueva C. Comparative analysis of sample preparation methods to handle the complexity of the blood fluid metabolome: when less is more. Anal Chem. 2012; 85(1): 341-348.

[59] Rogeberg M, Malerod H, Roberg-Larsen H, Aass C, Wilson SR. On-line solid phase extraction–liquid chromatography, with emphasis on modern bioanalysis and miniaturized systems. J Pharmaceut Biomed. 2014; 87: 120-129.

[60] Reyes-Garcés N, Gionfriddo E. Recent developments and applications of solid phase microextraction as a sample preparation approach for mass-spectrometry-based metabolomics and lipidomics. Trends Anal Chem. 2019; 113: 172-181.

[61] Mushtaq MY, Choi YH, Verpoorte R, Wilson EG. Extraction for metabolomics: access to the metabolome. Phytochem Anal. 2014; 25(4): 291-306.

[62] Teo CC, Chong WPK, Ho YS. Development and application of microwave-assisted extraction technique in biological sample preparation for small molecule analysis. Metabolomics. 2013; 9(5): 1109-1128.

[63] Mousavi F, Gionfriddo E, Carasek E, Souza-Silva EA, Pawliszyn J. Coupling solid phase microextraction to complementary separation platforms for metabotyping of E. coli metabolome in response to natural antibacterial agents. Metabolomics. 2016; 12: 1-13.

[64] Luque de Castro MD, Delgado-Povedano MM. Ultrasound: a subexploited tool for sample preparation in metabolomics. Anal Chim Acta. 2014; 806: 74-84.

[65] Perez de Souza L, Alseekh S, Scossa F, Fernie AR. Ultra-high-performance liquid chromatography high-resolution mass spectrometry variants for metabolomics research. Nat Methods. 2021; 18(7): 733-746.

[66] Kempa EE, Hollywood KA, Smith CA, Barran PE. High throughput screening of complex biological samples with mass spectrometry—from bulk measurements to single cell analysis. The Analyst. 2019; 144(3): 872-891.

[67] Ding J, Feng Y-Q. Mass spectrometry-based metabolomics for clinical study: recent progresses and applications. Trends Anal Chem. 2023; 158: 116896.

[68] Alseekh S, Aharoni A, Brotman Y, et al. Mass spectrometry-based metabolomics: a guide for annotation, quantification and best reporting practices. Nat Methods. 2021; 18(7): 747-756.

[69] Zeki OC, Eylem CC, Recber T, Kir S, Nemutlu E. Integration of GC-MS and LC-MS for untargeted metabolomics profiling. J Pharm Biomed Anal. 2020; 190: 113509.

[70] Gika HG, Wilson ID, Theodoridis GA. LC–MS-based holistic metabolic profiling. Problems, limitations, advantages, and future perspectives. J Chromatogr B. 2014; 966: 1-6.

[71] Tang DQ, Zou L, Yin XX, Ong CN. HILIC-MS for metabolomics: an attractive and complementary approach to RPLC-MS. Mass Spectrom Rev. 2014; 35(5): 574-600.

[72] Mamani-Huanca M, Villaseñor A, Gonzalez-Riano C, López-López Á, López-Gonzálvez Á, Barbas C. Capillary electrophoresis mass spectrometry-based untargeted metabolomics to approach disease diagnosis. Trends Anal Chem. 2023; 162: 117049.

[73] Drouin N, van Mever M, Zhang W, et al. Capillary electrophoresis-mass spectrometry at trial by metabo-ring: effective electrophoretic mobility for reproducible and robust compound annotation. Anal Chem. 2020; 92(20): 14103-14112.

[74] Dey A, Charrier B, Martineau E, et al. Hyperpolarized NMR metabolomics at natural 13C abundance. Anal Chem. 2020; 92(22): 14867-14871.

[75] Rankin NJ, Preiss D, Welsh P, et al. The emergence of proton nuclear magnetic resonance metabolomics in the cardiovascular arena as viewed from a clinical perspective. Atherosclerosis. 2014; 237(1): 287-300.

[76] Rabinowitz JD, Purdy JG, Vastag L, Shenk T, Koyuncu E. Metabolomics in drug target discovery. Cold Spring Harb Symp Quant Biol. 2011; 76(0): 235-246.

[77] Fillet M, Frédérich M. The emergence of metabolomics as a key discipline in the drug discovery process. Drug Discov Today: Technol. 2015; 13: 19-24.

[78] Hendriks MM, van Eeuwijk FA, Jellema RH, et al. Data-processing strategies for metabolomics studies. Trends Anal Chem. 2011; 30(10): 1685-1698.

[79] Boysen AK, Heal KR, Carlson LT, Ingalls AE. Best-matched internal standard normalization in liquid chromatography–mass spectrometry metabolomics applied to environmental samples. Anal Chem. 2018; 90(2): 1363-1369.

[80] Cai Y, Zhou Z, Zhu Z-J. Advanced analytical and informatic strategies for metabolite annotation in untargeted metabolomics. Trends Anal Chem. 2023; 158: 116903.

[81] Smith CA, O’Maille G, Want EJ, et al. METLIN a metabolite mass spectral database. Ther Drug Monit. 2005; 27(6): 747-751.

[82] Xue J, Guijas C, Benton HP, Warth B, Siuzdak G. METLIN MS(2) molecular standards database: a broad chemical and biological resource. Nat Methods. 2020; 17(10): 953-954.

[83] Sawada Y, Nakabayashi R, Yamada Y, et al. RIKEN tandem mass spectral database (ReSpect) for phytochemicals: a plant-specific MS/MS-based data resource and database. Phytochemistry. 2012; 82: 38-45.

[84] Kostyukevich Y, Zherebker A, Orlov A, et al. Hydrogen/deuterium and 16O/18O-exchange mass spectrometry boosting the reliability of compound identification. Anal Chem. 2020; 92(10): 6877-6885.

[85] Kind T, Liu K-H, Lee DY, DeFelice B, Meissen JK, Fiehn O. LipidBlast in silico tandem mass spectrometry database for lipid identification. Nat Methods. 2013; 10(8): 755-758.

[86] Smith CA, Want EJ, O’Maille G, Abagyan R, Siuzdak G. XCMS processing mass spectrometry data for metabolite profiling using nonlinear peak alignment, matching, and identification. Anal Chem. 2006; 78(3): 779-787.

[87] Forsberg EM, Huan T, Rinehart D, et al. Data processing, multi-omic pathway mapping, and metabolite activity analysis using XCMS Online. Nat Protoc. 2018; 13(4): 633-651.

[88] Huan T, Forsberg EM, Rinehart D, et al. Systems biology guided by XCMS Online metabolomics. Nat Methods. 2017; 14(5): 461-462.

[89] Pluskal T, Castillo S, Villar-Briones A, Orešič M. MZmine 2 Modular framework for processing, visualizing, and analyzing mass spectrometry-based molecular profile data. BMC Bioinformatics. 2010; 11: 395.

[90] Li S, Siddiqa A, Thapa M, Chi Y, Zheng S. Trackable and scalable LC-MS metabolomics data processing using asari. Nat Commun. 2023; 14(1): 4113.

[91] Barnes S. Overview of experimental methods and study design in metabolomics, and statistical and pathway considerations. In: Li S, ed. Computational Methods and Data Analysis for Metabolomics. 2020: 1-10. In. ed. Springer.

[92] Chong J, Soufan O, Li C, et al. MetaboAnalyst 4.0: towards more transparent and integrative metabolomics analysis. Nucleic Acids Res. 2018; 46(W1): W486-W494.

[93] Melamud E, Vastag L, Rabinowitz JD. Metabolomic analysis and visualization engine for LC–MS data. Anal Chem. 2010; 82(23): 9818-9826.

[94] Tsugawa H, Cajka T, Kind T, et al. MS-DIAL: data-independent MS/MS deconvolution for comprehensive metabolome analysis. Nat Methods. 2015; 12(6): 523-526.

[95] Xu S, Bai C, Chen Y, Yu L, Wu W, Hu K. Comparing univariate filtration preceding and succeeding PLS-DA analysis on the differential variables/metabolites identified from untargeted LC-MS metabolomics data. Anal Chim Acta. 2024; 1287: 342103.

[96] Liland KH. Multivariate methods in metabolomics–from pre-processing to dimension reduction and statistical analysis. Trends Anal Chem. 2011; 30(6): 827-841.

[97] Li W, Shao C, Li C, et al. Metabolomics: a useful tool for ischemic stroke research. J Pharm Anal. 2023; 13(9): 968-983.

[98] Griffiths WJ, Koal T, Wang Y, Kohl M, Enot DP, Deigner HP. Targeted metabolomics for biomarker discovery. Angew Chem Int Ed Engl. 2010; 49(32): 5426-5445.

[99] Johnson CH, Ivanisevic J, Siuzdak G. Metabolomics: beyond biomarkers and towards mechanisms. Nat rev Mol cell biol. 2016; 17(7): 451-459.

[100] Zhang Y, Zhou Y, Zhou Y, et al. TheMarker: a comprehensive database of therapeutic biomarkers. Nucleic Acids Res. 2024; 52(D1): D1450-D1464.

[101] Xu D, Dai X, Zhang L, et al. Mass spectrometry for biomarkers, disease mechanisms, and drug development in cerebrospinal fluid metabolomics. Trends Anal Chem. 2024; 173: 117626.

[102] Qiu S, Cai Y, Yao H, et al. Small molecule metabolites: discovery of biomarkers and therapeutic targets. Signal Transduct Tar. 2023; 8(1): 132.

[103] Karnovsky A, Li S. Pathway analysis for targeted and untargeted metabolomics. In: Li S, ed. Computational Methods and Data Analysis for Metabolomics. 2020: 387-400. In. ed. Springer.

[104] Wieder C, Bundy JG, Frainay C, et al. Avoiding the misuse of pathway analysis tools in environmental metabolomics. Environ Sci Technol. 2022; 56(20): 14219-14222.

[105] Patil KR, Wieder C, Frainay C, et al. Pathway analysis in metabolomics: recommendations for the use of over-representation analysis. Plos Comput Biol. 2021; 17(9): e1009105.

[106] Hamdalla MA, Rajasekaran S, Grant DF, Măndoiu II. Metabolic pathway predictions for metabolomics: a molecular structure matching approach. J Chem Inf Model. 2015; 55(3): 709-718.

[107] Kanehisa M, Sato Y. KEGG mapper for inferring cellular functions from protein sequences. Protein Sci. 2019; 29(1): 28-35.

[108] Karp PD, Billington R, Caspi R, et al. The BioCyc collection of microbial genomes and metabolic pathways. Brief Bioinform. 2019; 20(4): 1085-1093.

[109] Fabregat A, Jupe S, Matthews L, et al. The reactome pathway knowledgebase. Nucleic Acids Res. 2018; 46(D1): D649-D655.

[110] Jassal B, Matthews L, Viteri G, et al. The reactome pathway knowledgebase. Nucleic Acids Res. 2020; 48(D1): D498-D503.

[111] Jupe S, Ray K, Roca CD, et al. Interleukins and their signaling pathways in the reactome biological pathway database. J Allergy Clin Immun. 2018; 141(4): 1411-1416.

[112] Blackwell KT, Bohler A, Wu G, et al. Reactome from a WikiPathways perspective. Plos Comput Biol. 2016; 12(5): e1004941.

[113] Vitale GA, Geibel C, Minda V, Wang M, Aron AT, Petras D. Connecting metabolome and phenotype: recent advances in functional metabolomics tools for the identification of bioactive natural products. Nat Prod Rep. 2024; 41: 885-904.

[114] Guijas C, Montenegro-Burke JR, Warth B, Spilker ME, Siuzdak G. Metabolomics activity screening for identifying metabolites that modulate phenotype. Nat Biotechnol. 2018; 36(4): 316-320.

[115] Geiger R, Rieckmann JC, Wolf T, et al. L-Arginine modulates T cell metabolism and enhances survival and anti-tumor activity. Cell. 2016; 167(3): 829-842.

[116] Peng B, Su Y-b, Li H, et al. Exogenous alanine and/or glucose plus kanamycin kills antibiotic-resistant bacteria. Cell Metab. 2015; 21(2): 249-262.

[117] Scott SA, Fu J, Chang PV. Microbial tryptophan metabolites regulate gut barrier function via the aryl hydrocarbon receptor. Proc Natl Acad Sci USA. 2020; 117(32): 19376-19387.

[118] Sullivan LB, Luengo A, Danai LV, et al. Aspartate is an endogenous metabolic limitation for tumour growth. Nat Cell Biol. 2018; 20(7): 782-788.

[119] Garcia-Bermudez J, Baudrier L, La K, et al. Aspartate is a limiting metabolite for cancer cell proliferation under hypoxia and in tumours. Nat Cell Biol. 2018; 20(7): 775-781.

[120] Meléndez-Rodríguez F, Urrutia AA, Lorendeau D, et al. HIF1α suppresses tumor cell proliferation through inhibition of aspartate biosynthesis. Cell Rep. 2019; 26(9): 2257-2265.

[121] Luo C, Peng W, Kang J, et al. Glutamine regulates cell growth and casein synthesis through the CYTHs/ARFGAP1-Arf1-mTORC1 pathway in bovine mammary epithelial cells. J Agr Food Chem. 2021; 69(24): 6810-6819.

[122] Sun N, Liang Y, Chen Y, et al. Glutamine affects T24 bladder cancer cell proliferation by activating STAT3 through ROS and glutaminolysis. Int J Mol Med. 2019; 44: 2189-2200.

[123] Wang T, Hu L, Lu J, et al. Functional metabolomics revealed functional metabolic-characteristics of chronic hepatitis that is significantly differentiated from acute hepatitis in mice. Pharmacol Res. 2022; 180: 106248.

[124] Ruoppolo M, Caterino M, Albano L, et al. Targeted metabolomic profiling in rat tissues reveals sex differences. Sci Rep. 2018; 8(1): 4663.

[125] Deng M, Zhang X, Luo J, et al. Metabolomics analysis reveals differences in evolution between maize and rice. Plant J. 2020; 103(5): 1710-1722.

[126] Lindsay MA. Target discovery. Nat Rev Drug Discovery. 2003; 2(10): 831-838.

[127] Sioud M. Main approaches to target discovery and validation. In: Sioud M, ed. Emerging Strategies for Targets and Biomarker Discovery. Humana Press; 2007: 1-12. Target Discovery and Validation Reviews and Protocols. Volume.

[128] Dendrou CA, Petersen J, Rossjohn J, Fugger L. HLA variation and disease. Nat Rev Immunol. 2018; 18(5): 325-339.

[129] De Roeck A, Van Broeckhoven C, Sleegers K. The role of ABCA7 in Alzheimer’s disease: evidence from genomics, transcriptomics and methylomics. Acta Neuropathologica. 2019; 138(2): 201-220.

[130] Hocher B, Adamski J. Metabolomics for clinical use and research in chronic kidney disease. Nat Rev Nephrol. 2017; 13(5): 269-284.

[131] Weiss RH, Kim K. Metabolomics in the study of kidney diseases. Nat Rev Nephrol. 2011; 8(1): 22-33.

[132] Lin G, Lin L, Lin H, et al. KCNK3 inhibits proliferation and glucose metabolism of lung adenocarcinoma via activation of AMPK-TXNIP pathway. Cell Death Discov. 2022; 8(1): 360.

[133] Zhu Q, Dong Q, Wang X, Fu Y, Wu R, Wu T. Palmitic acid, a critical metabolite, aggravates cellular senescence through reactive oxygen species generation in Kawasaki disease. Front Pharmacol. 2022; 13: 809157.

[134] Cui H, Chen Y, Li K, et al. Untargeted metabolomics identifies succinate as a biomarker and therapeutic target in aortic aneurysm and dissection. Eur Heart J. 2021; 42(42): 4373-4385.

[135] Zhu Q, Yuan C, Dong X, et al. Bile acid metabolomics identifies chenodeoxycholic acid as a therapeutic agent for pancreatic necrosis. Cell Rep Med. 2023; 4(12): 101304.

[136] Saghatelian A, McKinney MK, Bandell M, Patapoutian A, Cravatt BF. A FAAH-regulated class of N-acyl taurines that activates TRP ion channels. Biochemistry. 2006; 45(30): 9007-9015.

[137] Ciborowski M, Martin-Ventura JL, Meilhac O, et al. Metabolites secreted by human atherothrombotic aneurysms revealed through a metabolomic approach. J Proteome Res. 2011; 10(3): 1374-1382.

[138] Urrutia AA, Mesa-Ciller C, Guajardo-Grence A, et al. HIF1α-dependent uncoupling of glycolysis suppresses tumor cell proliferation. Cell Rep. 2024; 43(4).

[139] Kato M, Li J, Chuang JL, Chuang DT. Distinct structural mechanisms for inhibition of pyruvate dehydrogenase kinase isoforms by AZD7545, dichloroacetate, and radicicol. Structure. 2007; 15(8): 992-1004.

[140] Zhang W, Zhang S-L, Hu X, Tam KY. Targeting tumor metabolism for cancer treatment: is pyruvate dehydrogenase kinases (PDKs) a viable anticancer target. Int J Biol Sci. 2015; 11(12): 1390.

[141] Woolbright BL, Rajendran G, Harris RA, Taylor III JA. Metabolic flexibility in cancer: targeting the pyruvate dehydrogenase kinase: pyruvate dehydrogenase axis. Mol Cancer Ther. 2019; 18(10): 1673-1681.

[142] Takubo K, Nagamatsu G, Kobayashi CI, et al. Regulation of glycolysis by Pdk functions as a metabolic checkpoint for cell cycle quiescence in hematopoietic stem cells. Cell Stem Cell. 2013; 12(1): 49-61.

[143] Pérez-Díaz AJ, Núñez-Sánchez MÁ, Ramos-Molina B. Revisiting liver metabolism through acetyl-CoA carboxylase inhibition. Trends Endocrin Metab. 2024; 35(7): 563-565.

[144] Wu X, Yu Y, Huang T. Synthesis and biological evaluation of 4-phenoxy-phenyl isoxazoles as novel acetyl-CoA carboxylase inhibitors. J Enzym Inhib Med Chem. 2021; 36(1): 1236-1247.

[145] Chen L, Duan Y, Wei H, et al. Acetyl-CoA carboxylase (ACC) as a therapeutic target for metabolic syndrome and recent developments in ACC1/2 inhibitors. Expert Opin Inv Drug. 2019; 28(10): 917-930.

[146] Wang D, Hiebl V, Schachner D, et al. Soraphen A enhances macrophage cholesterol efflux via indirect LXR activation and ABCA1 upregulation. Biochem Pharmacol. 2020; 177: 114022.

[147] Li S, Qiu L, Wu B, et al. TOFA suppresses ovarian cancer cell growth in vitro and in vivo. Mol Med Rep. 2013; 8(2): 373-378.

[148] Harwood HJ, Petras SF, Shelly LD, et al. Isozyme-nonselective N-substituted bipiperidylcarboxamide acetyl-CoA carboxylase inhibitors reduce tissue malonyl-CoA concentrations, inhibit fatty acid synthesis, and increase fatty acid oxidation in cultured cells and in experimental animals. J Biol Chem. 2003; 278(39): 37099-37111.

[149] Trautwein C, Zizmare L, Mäurer I, et al. Tissue metabolites in diffuse glioma and their modulations by IDH1 mutation, histology, and treatment. JCI Insight. 2022; 7(3): e153526.

[150] Dang L, White DW, Gross S, et al. Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. Nature. 2009; 462(7274): 739-744.

[151] Grassian AR, Parker SJ, Davidson SM, et al. IDH1 mutations alter citric acid cycle metabolism and increase dependence on oxidative mitochondrial metabolism. Cancer Res. 2014; 74(12): 3317-3331.

[152] Miyata S, Tominaga K, Sakashita E, et al. Comprehensive metabolomic analysis of IDH1 R132H clinical glioma samples reveals suppression of β-oxidation due to carnitine deficiency. Sci Rep. 2019; 9(1): 9787.

[153] Zhou L, Wang Z, Hu C, et al. Integrated metabolomics and lipidomics analyses reveal metabolic reprogramming in human glioma with IDH1 mutation. J Proteome Res. 2018; 18(3): 960-969.

[154] Zhao L, Dong M, Ren M, Li C, Zheng H, Gao H. Metabolomic analysis identifies lactate as an important pathogenic factor in diabetes-associated cognitive decline rats. Mol Cell Proteomics. 2018; 17(12): 2335-2346.

[155] Oshima N, Ishida R, Kishimoto S, et al. Dynamic imaging of LDH inhibition in tumors reveals rapid in vivo metabolic rewiring and vulnerability to combination therapy. Cell Rep. 2020; 30(6): 1798-1810.

[156] Hicks KG, Cluntun AA, Schubert HL, et al. Protein-metabolite interactomics of carbohydrate metabolism reveal regulation of lactate dehydrogenase. Science. 2023; 379(6636): 996-1003.

[157] Abdul KSM, Jovanović S, Du Q, Sukhodub A, Jovanović A. Mild hypoxia in vivo regulates cardioprotective SUR2A: a role for Akt and LDH. BBA—Mol Basis Dis. 2015; 1852(5): 709-719.

[158] Zhang H, Guo F, Zhu G. Cryptosporidium lactate dehydrogenase is associated with the parasitophorous vacuole membrane and is a potential target for developing therapeutics. PLoS pathogens. 2015; 11(11): e1005250.

[159] Matés JM, Di Paola FJ, Campos-Sandoval JA, Mazurek S, Márquez J. Therapeutic Targeting of Glutaminolysis as an Essential Strategy to Combat Cancer. Elsevier; 2020: 34-43.

[160] Yu W, Yang X, Zhang Q, Sun L, Yuan S, Xin Y. Targeting GLS1 to cancer therapy through glutamine metabolism. Clin Transl Oncol. 2021; 23: 2253-2268.

[161] Koch K, Hartmann R, Tsiampali J, et al. A comparative pharmaco-metabolomic study of glutaminase inhibitors in glioma stem-like cells confirms biological effectiveness but reveals differences in target-specificity. Cell Death Discov. 2020; 6(1): 20.

[162] Kim S, Jeon JS, Choi YJ, Baek GH, Kim SK, Kang KW. Heterogeneity of glutamine metabolism in acquired-EGFR-TKI-resistant lung cancer. Life Sci. 2022; 291: 120274.

[163] Wang J, Yang D, Shen X, et al. BPTES inhibits anthrax lethal toxin-induced inflammatory response. Int Immunopharmacol. 2020; 85: 106664.

[164] Cederkvist H, Kolan SS, Wik JA, Sener Z, Skålhegg BS. Identification and characterization of a novel glutaminase inhibitor. FEBS Open Bio. 2022; 12(1): 163-174.

[165] Carbone D, Vestuto V, Ferraro MR, et al. Metabolomics-assisted discovery of a new anticancer GLS-1 inhibitor chemotype from a nortopsentin-inspired library: from phenotype screening to target identification. Eur J Med Chem. 2022; 234: 114233.

[166] Xu T, Zhao H, Wang M, Chow A, Fang M. Metabolomics andIn silicodocking-directed discovery of small-molecule enzyme targets. Anal Chem. 2021; 93(6): 3072-3081.

[167] Gao W, Gao S, Zhang Y, et al. Altered metabolic profiles and targets relevant to the protective effect of acteoside on diabetic nephropathy in db/db mice based on metabolomics and network pharmacology studies. J Ethnopharmacol. 2024; 318: 117073.

[168] Dong XM, Chen L, Wu P, et al. Targeted metabolomics reveals PFKFB3 as a key target for elemene-mediated inhibition of glycolysis in prostate cancer cells. Phytomedicine. 2024; 123: 155185.

[169] He J, Wang L, Wang Y, Li Z, Chen F, Liu Z. Metabolomics combined with network pharmacology uncovers effective targets of Tao-Hong-Si-Wu Decoction for its protection from sepsis-associated acute lung injury. J Anal Test. 2023; 7(2): 172-186.

[170] Calabrese EJ. The emergence of the dose-response concept in biology and medicine. Int J Mol Sci. 2016; 17(12): 2034.

[171] Chen Y-Y, Chen J-Q, Tang Y-P, et al. Integrated dose–response metabolomics with therapeutic effects and adverse reactions may demystify the dosage of traditional Chinese medicine. Chin Med. 2022; 17(1): 130.

[172] Rani J, Dhull SB, Rose PK, Kidwai MK. Drug-induced liver injury and anti-hepatotoxic effect of herbal compounds: a metabolic mechanism perspective. Phytomedicine. 2024; 122: 155142.

[173] Feng J, Zheng Y, Ma W, et al. Multitarget antibacterial drugs: an effective strategy to combat bacterial resistance. Pharmacol Therapeut. 2023; 252: 108550.

[174] Yao C-H, Wang L, Stancliffe E, et al. Dose-response metabolomics to understand biochemical mechanisms and off-target drug effects with the TOXcms software. Anal Chem. 2019; 92(2): 1856-1864.

[175] Pink M, Verma N, Zerries A, Schmitz-Spanke S. Dose-dependent response to 3-nitrobenzanthrone exposure in human urothelial cancer cells. Chem Res Toxicol. 2017; 30(10): 1855-1864.

[176] Zhao H, Liu M, Lv Y, Fang M. Dose-response metabolomics and pathway sensitivity to map molecular cartography of bisphenol A exposure. Environ Int. 2022; 158: 106893.

[177] Sakallioglu IT, Barletta RG, Dussault PH, Powers R. Deciphering the mechanism of action of antitubercular compounds with metabolomics. Comput Struct Biotechnol J. 2021; 19: 4284-4299.

[178] Soumoy L, Ghanem GE, Saussez S, Journe F. Bufalin for an innovative therapeutic approach against cancer. Pharmacol Res. 2022; 184: 106442.

[179] Tao C, Wang J, Gu Z, et al. Network pharmacology and metabolomics elucidate the underlying mechanisms of Venenum Bufonis in the treatment of colorectal cancer. J Ethnopharmacol. 2023; 317: 116695.

[180] Colas S, Marie B, Milhe-Poutingon M, et al. Meta-metabolomic responses of river biofilms to cobalt exposure and use of dose-response model trends as an indicator of effects. J Hazard Mater. 2024; 470: 134099.

[181] Wang T-Y, Guo R, Hu L-L, Liu J-J, Lu H-T. Mass spectrometry-based targeted metabolomics revealed the regulatory roles of magnesium on biofilm formation in Escherichia coli by targeting functional metabolites. J Anal Test. 2022; 6(2): 89-97.

[182] Westi EW, Andersen JV, Aldana BI. Using stable isotope tracing to unravel the metabolic components of neurodegeneration: focus on neuron-glia metabolic interactions. Neurobiol Dis. 2023; 182: 106145.

[183] Moiz B, Sriram G, Clyne AM. Interpreting metabolic complexity via isotope-assisted metabolic flux analysis. Trends Biochem Sci. 2023; 48(6): 553-567.

[184] Liang L, Sun F, Wang H, Hu Z. Metabolomics, metabolic flux analysis and cancer pharmacology. Pharmacol Therapeut. 2021; 224: 107827.

[185] Creager AN. Life Atomic: A History of Radioisotopes in Science and Medicine. University of Chicago Press; 2019.

[186] Schoenheimer R, Rittenberg D. Deuterium as an indicator in the study of intermediary metabolism. Science. 1935; 82(2120): 156-157.

[187] Jang C, Chen L, Rabinowitz JD. Metabolomics and isotope tracing. Cell. 2018; 173(4): 822-837.

[188] Giafaglione JM, Crowell PD, Delcourt AML, et al. Prostate lineage-specific metabolism governs luminal differentiation and response to antiandrogen treatment. Nat Cell Biol. 2023; 25(12): 1821-1832.

[189] Kambhampati S, Hubbard AH, Koley S, et al. SIMPEL: using stable isotopes to elucidate dynamics of context specific metabolism. Commun Biol. 2024; 7(1): 172.

[190] Bartman CR, Faubert B, Rabinowitz JD, DeBerardinis RJ. Metabolic pathway analysis using stable isotopes in patients with cancer. Nat Rev Cancer. 2023; 23(12): 863-878.

[191] Wilkinson DJ, Brook MS, Smith K, Atherton PJ. Stable isotope tracers and exercise physiology: past, present and future. J Physiol. 2016; 595(9): 2873-2882.

[192] Deja S, Fletcher JA, Kim CW, et al. Hepatic malonyl-CoA synthesis restrains gluconeogenesis by suppressing fat oxidation, pyruvate carboxylation, and amino acid availability. Cell Metab. 2024; 36(5): P1088-1104.

[193] Shi X, Xi B, Jasbi P, Turner C, Jin Y, Gu H. Comprehensive isotopic targeted mass spectrometry: reliable metabolic flux analysis with broad coverage. Anal Chem. 2020; 92(17): 11728-11738.

[194] Antoniewicz MR. A guide to metabolic flux analysis in metabolic engineering: methods, tools and applications. Metab Eng. 2021; 63: 2-12.

[195] Zamboni N, Saghatelian A, Patti GJ. Defining the metabolome: size, flux, and regulation. Mol cell. 2015; 58(4): 699-706.

[196] Dai Z, Locasale JW. Understanding metabolism with flux analysis: from theory to application. Metab Eng. 2017; 43: 94-102.

[197] Cheah YE, Young JD. Isotopically nonstationary metabolic flux analysis (INST-MFA): putting theory into practice. Curr Opin Biotechnol. 2018; 54: 80-87.

[198] Antoniewicz MR. Parallel labeling experiments for pathway elucidation and 13C metabolic flux analysis. Curr Opin Biotech. 2015; 36: 91-97.

[199] Huß S, Nikoloski Z. Systematic comparison of local approaches for isotopically nonstationary metabolic flux analysis. Front Plant Sci. 2023; 14: 1178239.

[200] Rahim M, Ragavan M, Deja S, Merritt ME, Burgess SC, Young JD. INCA 2.0: a tool for integrated, dynamic modeling of NMR-and MS-based isotopomer measurements and rigorous metabolic flux analysis. Metab Eng. 2022; 69: 275-285.

[201] Kajihata S, Furusawa C, Matsuda F, Shimizu H. OpenMebius: an open source software for isotopically nonstationary 13 C-based metabolic flux analysis. Biomed Res Int. 2014; 2014: 627014.

[202] Lugar DJ, Sriram G. Isotope-assisted metabolic flux analysis as an equality-constrained nonlinear program for improved scalability and robustness. Plos Comput Biol. 2022; 18(3): e1009831.

[203] Zhang Y, Zhuang H, Gu Y, Zou D. P003 metabolic reprogramming in intestinal fibrosis: integrating metabolomics, single-cell transcriptomics and isotope tracing. J Crohns Colitis. 2024; 18: i246-i246. Supplement_1.

[204] Cobbold SA, V Tutor M, Frasse P, et al. Non-canonical metabolic pathways in the malaria parasite detected by isotope-tracing metabolomics. Mol Syst Biol. 2021; 17(4): e10023.

[205] Liu X, Romero IL, Litchfield LM, Lengyel E, Locasale JW. Metformin targets central carbon metabolism and reveals mitochondrial requirements in human cancers. Cell Metab. 2016; 24(5): 728-739.

[206] Tian J, wang x, Wu W, Zhao Y, Ling-hu T, Qin X. Stable isotope tracer technique and network pharmacology to reveal antidepressant targets and active components of Xiaoyao San. Chem Biodivers. 2024; 21(4): e202301736.

[207] Nwosu ZC, Ward MH, Sajjakulnukit P, et al. Uridine-derived ribose fuels glucose-restricted pancreatic cancer. Nature. 2023; 618(7963): 151-158.

[208] Kim J, Hu Z, Cai L, et al. CPS1 maintains pyrimidine pools and DNA synthesis in KRAS/LKB1-mutant lung cancer cells. Nature. 2017; 546(7656): 168-172.

[209] Trifonova O, Knight RA, Lisitsa A, Melino G, Antonov AV. Exploration of individuality in drug metabolism by high-throughput metabolomics: the fast line for personalized medicine. Drug Discov Today. 2016; 21(1): 103-110.

[210] Fuhrer T, Zamboni N. High-throughput discovery metabolomics. Curr Opin Biotechnol. 2015; 31: 73-78.

[211] de Raad M, Fischer CR, Northen TR. High-throughput platforms for metabolomics. Curr Opin Chem Biol. 2016; 30: 7-13.

[212] Plumb RS, Gethings LA, Rainville PD, et al. Advances in high throughput LC/MS based metabolomics: a review. Trends Anal Chem. 2023; 160: 116954.

[213] Rainville PD, Wilson ID, Nicholson JK, et al. Ion mobility spectrometry combined with ultra performance liquid chromatography/mass spectrometry for metabolic phenotyping of urine: effects of column length, gradient duration and ion mobility spectrometry on metabolite detection. Anal Chim Acta. 2017; 982: 1-8.

[214] Guder JC, Schramm T, Sander T, Link H. Time-Optimized isotope ratio LC-MS/MS for high-throughput quantification of primary metabolites. Anal Chem. 2017; 89(3): 1624-1631.

[215] Draper J, Lloyd AJ, Goodacre R, Beckmann M. Flow infusion electrospray ionisation mass spectrometry for high throughput, non-targeted metabolite fingerprinting: a review. Metabolomics. 2012; 9(S1): 4-29.

[216] Marques C, Liu L, Duncan KD, Lanekoff I. A direct infusion probe for rapid metabolomics of low-volume samples. Anal Chem. 2022; 94(37): 12875-12883.

[217] Plekhova V, De Windt K, De Spiegeleer M, De Graeve M, Vanhaecke L. Recent advances in high-throughput biofluid metabotyping by direct infusion and ambient ionization mass spectrometry. Trends Anal Chem. 2023; 168: 117287.

[218] Southam AD, Weber RJ, Engel J, Jones MR, Viant MR. A complete workflow for high-resolution spectral-stitching nanoelectrospray direct-infusion mass-spectrometry-based metabolomics and lipidomics. Nat Protoc. 2016; 12(2): 310-328.

[219] Orton DJ, Tfaily MM, Moore RJ, et al. A customizable flow injection system for automated, high throughput, and time sensitive ion mobility spectrometry and mass spectrometry measurements. Anal Chem. 2018; 90(1): 737-744.

[220] Kurbanoglu S, Unal MA, Ozkan SA. Recent developments on electrochemical flow injection in pharmaceuticals and biologically important compounds. Electrochimica Acta. 2018; 287: 135-148.

[221] Fuhrer T, Heer D, Begemann B, Zamboni N. High-throughput, accurate mass metabolome profiling of cellular extracts by flow injection-time-of-flight mass spectrometry. Anal Chem. 2011; 83(18): 7074-7080.

[222] Vignoli A, Ghini V, Meoni G, et al. High-throughput metabolomics by 1D NMR. Angew Chem Int Ed Engl. 2019; 58(4): 968-994.

[223] Bajorath J. Integration of virtual and high-throughput screening. Nat Rev Drug Discov. 2002; 1(11): 882-894.

[224] Li L, Liu X, Bai Y, Yao B, Luo H, Tu T. High-Throughput screening techniques for the selection of thermostable enzymes. J Agric Food Chem. 2024; 72(8): 3833-3845.

[225] Strutt R, Xiong B, Abegg VF, Dittrich PS. Open microfluidics: droplet microarrays as next generation multiwell plates for high throughput screening. Lab Chip. 2024; 24(5): 1064-1075.

[226] Mayr LM, Bojanic D. Novel trends in high-throughput screening. Curr Opin Pharmacol. 2009; 9(5): 580-588.

[227] Robert PH, Andrew JP. High-throughput screening: new technology for the 21st century. Curr Opin Chem Biol. 2000; 4(4): 445-451.

[228] Clare RH, Dawson CA, Westhorpe A, et al. Snakebite drug discovery: high-throughput screening to identify novel snake venom metalloproteinase toxin inhibitors. Front Pharmacol. 2023; 14: 1328950.

[229] Sévin DC, Fuhrer T, Zamboni N, Sauer U. Nontargeted in vitro metabolomics for high-throughput identification of novel enzymes in Escherichia coli. Nat Methods. 2017; 14(2): 187-194.

[230] Garana BB, Graham NA. Metabolomics paves the way for improved drug target identification. Mol Syst Biol. 2022; 18(2): e10914.

[231] Campos AI, Zampieri M. Metabolomics-driven exploration of the chemical drug space to predict combination antimicrobial therapies. Mol Cell. 2019; 74(6): 1291-1303.

[232] Holbrook-Smith D, Durot S, Sauer U. High-throughput metabolomics predicts drug–target relationships for eukaryotic proteins. Mol Syst Biol. 2022; 18(2): e10767.

[233] Lim H, Lee S, Jin JS, Kim MS. High-throughput quantitative analysis of amino acids in freeze-dried drops using time-of-flight secondary ion mass spectrometry. Anal Chem. 2024; 96(9): 3717-3721.

[234] Zampieri M, Sekar K, Zamboni N, Sauer U. Frontiers of high-throughput metabolomics. Curr Opin Chem Biol. 2017; 36: 15-23.

[235] Canzler S, Schor J, Busch W, et al. Prospects and challenges of multi-omics data integration in toxicology. Arch Toxicol. 2020; 94: 371-388.

[236] Krassowski M, Das V, Sahu SK, Misra BB. State of the field in multi-omics research: from computational needs to data mining and sharing. Front Genet. 2020; 11: 610798.

[237] Yoon SH, Han M-J, Jeong H, et al. Comparative multi-omics systems analysis of Escherichia coli strains B and K-12. Genome Biol. 2012; 13: R37.

[238] Cisek K, Krochmal M, Klein J, Mischak H. The application of multi-omics and systems biology to identify therapeutic targets in chronic kidney disease. Nephrol Dial Transpl. 2016; 31(12): 2003-2011.

[239] Shao X, Ji F, Wang Y, et al. Integrative chemical proteomics-metabolomics approach reveals Acaca/Acacb as direct molecular targets of PFOA. Anal Chem. 2018; 90(18): 11092-11098.

[240] Sheng N, Zhang Z, Zheng H, et al. Scutellarin rescued mitochondrial damage through ameliorating mitochondrial glucose oxidation via the Pdk-Pdc axis. Adv Sci (Weinh). 2023; 10(32): e2303584.

[241] Wang Y, Zhao J, Xu Y, et al. Uncovering SOD3 and GPX4 as new targets of Benzo [α] pyrene-induced hepatotoxicity through metabolomics and chemical proteomics. Redox Biol. 2023; 67: 102930.

[242] Ouyang J, Feng Y, Zhang Y, et al. Integration of metabolomics and transcriptomics reveals metformin suppresses thyroid cancer progression via inhibiting glycolysis and restraining DNA replication. Biomed Pharmacother. 2023; 168: 115659.

[243] Lord SR, Collins JM, Cheng WC, et al. Transcriptomic analysis of human primary breast cancer identifies fatty acid oxidation as a target for metformin. Br J Cancer. 2020; 122(2): 258-265.

[244] Lee J, Yesilkanal AE, Wynne JP, et al. Effective breast cancer combination therapy targeting BACH1 and mitochondrial metabolism. Nature. 2019; 568(7751): 254-258.

[245] Robinson SW, Fernandes M, Husi H. Current advances in systems and integrative biology. Comput Struct Biotechnol. 2014; 11(18): 35-46.

[246] Ebbels TM, Cavill R. Bioinformatic methods in NMR-based metabolic profiling. Prog Nucl Mag Res Sp. 2009; 55(4): 361-374.

[247] Bersanelli M, Mosca E, Remondini D, et al. Methods for the integration of multi-omics data: mathematical aspects. BMC Bioinformatics. 2016; 17: 167-177.

[248] Fondi M, Liò P. Multi-omics and metabolic modelling pipelines: challenges and tools for systems microbiology. Microbiol Res. 2015; 171: 52-64.

[249] Wörheide MA, Krumsiek J, Kastenmüller G, Arnold M. Multi-omics integration in biomedical research–a metabolomics-centric review. Anal Chim Acta. 2021; 1141: 144-162.

[250] Vandereyken K, Sifrim A, Thienpont B, Voet T. Methods and applications for single-cell and spatial multi-omics. Nat Rev Genet. 2023; 24(8): 494-515.

[251] Lillja J, Duncan KD, Lanekoff I. Ion-to-Image, i2i, a mass spectrometry imaging data analysis platform for continuous ionization techniques. Anal Chem. 2023; 95(31): 11589-11595.

[252] He MJ, Pu W, Wang X, Zhang W, Tang D, Dai Y. Comparing DESI-MSI and MALDI-MSI mediated spatial metabolomics and their applications in cancer studies. Front Oncol. 2022; 12: 891018.

[253] Ma X, Fernandez FM. Advances in mass spectrometry imaging for spatial cancer metabolomics. Mass Spectrom Rev. 2024; 43(2): 235-268.

[254] Song X, Li C, Meng Y. Mass spectrometry imaging advances and application in pharmaceutical research. Acta Materia Medica. 2022; 1(4): 507-533.

[255] Zhou Q, Fulop A, Hopf C. Recent developments of novel matrices and on-tissue chemical derivatization reagents for MALDI-MSI. Anal Bioanal Chem. 2021; 413(10): 2599-2617.

[256] Buchberger AR, DeLaney K, Johnson J, Li L. Mass spectrometry imaging: a review of emerging advancements and future insights. Anal Chem. 2018; 90(1): 240.

[257] He Q, Sun C, Liu J, Pan Y. MALDI-MSI analysis of cancer drugs: significance, advances, and applications. Trend Anal Chem. 2021; 136.

[258] Spengler B. Mass spectrometry imaging of biomolecular information. Anal Chem. 2015; 87(1): 64-82.

[259] Ma S, Leng Y, Li X, Meng Y, Yin Z, Hang W. High spatial resolution mass spectrometry imaging for spatial metabolomics: advances, challenges, and future perspectives. Trends Anal Chem. 2023; 159: 116902.

[260] Kumar R, Zemaitis KJ, Fulcher JM, Pasa-Tolic L. Advances in mass spectrometry-enabled at single-cell resolution. Curr Opin Biotechnol. 2024; 87: 103096.

[261] Rappez L, Stadler M, Triana S, et al. SpaceM reveals metabolic states of single cells. Nat Methods. 2021; 18(7): 799-805.

[262] Barré FP, Paine MR, Flinders B, et al. Enhanced sensitivity using MALDI imaging coupled with laser postionization (MALDI-2) for pharmaceutical research. Anal Chem. 2019; 91(16): 10840-10848.

[263] Lan Y, Zou Z, Yang Z. Single Cell mass spectrometry: towards quantification of small molecules in individual cells. Trends Anal Chem. 2024; 174: 117657.

[264] Wang H-J, Li B, Zhang M-T, et al. Mass spectrometry and mass spectrometry imaging-based thyroid cancer analysis. J Anal Test. 2022; 6(3): 235-246.

[265] Li L, Zang Q, Li X, et al. Spatiotemporal pharmacometabolomics based on ambient mass spectrometry imaging to evaluate the metabolism and hepatotoxicity of amiodarone in HepG2 spheroids. J Pharm Anal. 2023; 13(5): 483-493.

[266] Huang H, Ouyang D, Lin Z-A. Recent advances in surface-assisted laser desorption/ionization mass spectrometry and its imaging for small molecules. J Anal Test. 2022; 6(3): 217-234.

[267] Zivko C, Hahm TH, Tressler C, Brown D, Glunde K, Mahairaki V. Mass spectrometry imaging of organoids to improve preclinical research. Adv Healthc Mater. 2024:2302499.

[268] Chughtai K, Heeren RM. Mass spectrometric imaging for biomedical tissue analysis. Chem Rev. 2010; 110(5): 3237-3277.

[269] Soltwisch J, Kettling H, Vens-Cappell S, Wiegelmann M, Müthing J, Dreisewerd K. Mass spectrometry imaging with laser-induced postionization. Science. 2015; 348(6231): 211-215.

[270] Dunham SJ, Ellis JF, Li B, Sweedler JV. Mass spectrometry imaging of complex microbial communities. Accounts Chem Res. 2016; 50(1): 96-104.

[271] Zang Q, Sun C, Chu X, et al. Spatially resolved metabolomics combined with multicellular tumor spheroids to discover cancer tissue relevant metabolic signatures. Anal Chim Acta. 2021; 1155: 338342.

[272] Strittmatter N, Richards FM, Race AM, et al. Method to visualize the intratumor distribution and impact of gemcitabine in pancreatic ductal adenocarcinoma by multimodal imaging. Anal Chem. 2022; 94(3): 1795-1803.

[273] Liu Y, Zhang X, Yang S, et al. Integrated mass spectrometry imaging reveals spatial-metabolic alteration in diabetic cardiomyopathy and the intervention effects of ferulic acid. J Pharm Anal. 2023; 13(12): 1496-1509.

[274] Sun C, Li T, Song X, et al. Spatially resolved metabolomics to discover tumor-associated metabolic alterations. Proc Natl Acad Sci USA. 2019; 116(1): 52-57.

[275] Sun C, Wang F, Zhang Y, Yu J, Wang X. Mass spectrometry imaging-based metabolomics to visualize the spatially resolved reprogramming of carnitine metabolism in breast cancer. Theranostics. 2020; 10(16): 7070-7082.

[276] Jin B, Pang X, Zang Q, et al. Spatiotemporally resolved metabolomics and isotope tracing reveal CNS drug targets. Acta Pharm Sin B. 2023; 13(4): 1699-1710.

[277] Conroy LR, Clarke HA, Allison DB, et al. Spatial metabolomics reveals glycogen as an actionable target for pulmonary fibrosis. Nat Commun. 2023; 14(1): 2759.

[278] Rompp A, Guenther S, Takats Z, Spengler B. Mass spectrometry imaging with high resolution in mass and space (HR(2) MSI) for reliable investigation of drug compound distributions on the cellular level. Anal Bioanal Chem. 2011; 401(1): 65-73.

[279] Zamboni N. 13C metabolic flux analysis in complex systems. Curr Opin Biotechnol. 2011; 22(1): 103-108.

[280] Wang L, Xing X, Zeng X, et al. Spatially resolved isotope tracing reveals tissue metabolic activity. Nat Methods. 2022; 19(2): 223-230.

[281] Schwaiger-Haber M, Stancliffe E, Anbukumar DS, et al. Using mass spectrometry imaging to map fluxes quantitatively in the tumor ecosystem. Nat Commun. 2023; 14(1): 2876.

[282] Planque M, Igelmann S, Ferreira Campos AM, Fendt S-M. Spatial metabolomics principles and application to cancer research. Curr Opin Chem Biol. 2023; 76: 102362.

[283] Sun C, Wang A, Zhou Y, et al. Spatially resolved multi-omics highlights cell-specific metabolic remodeling and interactions in gastric cancer. Nat Commun. 2023; 14(1): 2692.

[284] Seydel C. Single-cell metabolomics hits its stride. Nat Methods. 2021; 18(12): 1452-1456.

[285] Carter B, Zhao K. The epigenetic basis of cellular heterogeneity. Nat Rev Genet. 2021; 22(4): 235-250.

[286] Tang DG. Understanding cancer stem cell heterogeneity and plasticity. Cell Res. 2012; 22(3): 457-472.

[287] Prasetyanti PR, Medema JP. Intra-tumor heterogeneity from a cancer stem cell perspective. Mol Cancer. 2017; 16(1): 41.

[288] Brooks MD, Burness ML, Wicha MS. Therapeutic implications of cellular heterogeneity and plasticity in breast cancer. Cell Stem Cell. 2015; 17(3): 260-271.

[289] Aum DJ, Kim DH, Beaumont TL, Leuthardt EC, Dunn GP, Kim AH. Molecular and cellular heterogeneity: the hallmark of glioblastoma. Neurosurg Focus. 2014; 37(6): E11.

[290] Kemper K, Sprick MR, de Bree M, et al. The AC133 epitope, but not the CD133 protein, is lost upon cancer stem cell differentiation. Cancer Res. 2010; 70(2): 719-729.

[291] Xu T, Li H, Dou P, et al. Concentric hybrid nanoelectrospray ionization-atmospheric pressure chemical ionization source for high-coverage mass spectrometry analysis of single-cell metabolomics. Adv Sci (Weinh). 2024; 11(16): e2306659.

[292] Wang Y, Navin NE. Advances and applications of single-cell sequencing technologies. Mol Cell. 2015; 58(4): 598-609.

[293] Nawy T. Single-cell sequencing. Nat Methods. 2014; 11(1): 18.

[294] Shapiro E, Biezuner T, Linnarsson S. Single-cell sequencing-based technologies will revolutionize whole-organism science. Nat Rev Genet. 2013; 14(9): 618-630.

[295] Patel AP, Tirosh I, Trombetta JJ, et al. Single-cell RNA-seq highlights intratumoral heterogeneity in primary glioblastoma. Science. 2014; 344(6190): 1396-1401.

[296] Venteicher AS, Tirosh I, Hebert C, et al. Decoupling genetics, lineages, and microenvironment in IDH-mutant gliomas by single-cell RNA-seq. Science. 2017; 355(6332): eaai8478.

[297] Dempsey LA. CyTOF analysis of anti-tumor responses. Nat Immunol. 2017; 18(3): 254.

[298] Iyer A, Hamers AAJ, Pillai AB. CyTOF((R)) for the masses. Front Immunol. 2022; 13: 815828.

[299] Chen J, Chu Z, Zhang Q, et al. STEP: profiling cellular-specific targets and pathways of bioactive small molecules in tissues via integrating single-cell transcriptomics and chemoproteomics. Chem Sci. 2024; 15(12): 4313-4321.

[300] Chen X, Sun M, Yang Z. Single cell mass spectrometry analysis of drug-resistant cancer cells: metabolomics studies of synergetic effect of combinational treatment. Anal Chim Acta. 2022; 1201: 339621.

[301] Sun M, Chen X, Yang Z. Single cell mass spectrometry studies reveal metabolomic features and potential mechanisms of drug-resistant cancer cell lines. Anal Chim Acta. 2022; 1206: 339761.

[302] Liu R, Sun M, Zhang G, Lan Y, Yang Z. Towards early monitoring of chemotherapy-induced drug resistance based on single cell metabolomics: combining single-probe mass spectrometry with machine learning. Anal Chim Acta. 2019; 1092: 42-48.

[303] Earl DC, Ferrell PB, Leelatian N, et al. Discovery of human cell selective effector molecules using single cell multiplexed activity metabolomics. Nat Commun. 2018; 9(1): 39.

[304] Zhu H, Li Q, Liao T, et al. Metabolomic profiling of single enlarged lysosomes. Nat Methods. 2021; 18(7): 788-798.

[305] Guo S, Zhang C, Le A. The limitless applications of single-cell metabolomics. Curr Opin Biotechnol. 2021; 71: 115-122.

[306] Bithi SS, Vanapalli SA. Microfluidic cell isolation technology for drug testing of single tumor cells and their clusters. Sci Rep. 2017; 7(1): 41707.

[307] Ali A, Abouleila Y, Shimizu Y, et al. Single-cell metabolomics by mass spectrometry: advances, challenges, and future applications. Trends Anal Chem. 2019; 120: 115436.

[308] Liu Y-L, Zhao Y-X, Li Y-B, et al. Recent advances of nanoelectrodes for single-cell electroanalysis: from extracellular, intercellular to intracellular. J Anal Test. 2022; 6(2): 178-192.

[309] Heinemann M, Zenobi R. Single cell metabolomics. Curr Opin Biotechnol. 2011; 22(1): 26-31.

[310] Zhang D, Qiao L. Microfluidics coupled mass spectrometry for single cell multi-omics. Small Methods. 2024; 8(1): e2301179.

[311] Zenobi R. Single-cell metabolomics: analytical and biological perspectives. Science. 2013; 342(6163): 1243259.

[312] Cao J, Yao QJ, Wu J, et al. Deciphering the metabolic heterogeneity of hematopoietic stem cells with single-cell resolution. Cell Metab. 2024; 36(1): 209-221.

[313] Ma A, Xin G, Ma Q. The use of single-cell multi-omics in immuno-oncology. Nat Commun. 2022; 13(1): 2728.

[314] Wu J, Xu QQ, Jiang YR, et al. One-shot single-cell proteome and metabolome analysis strategy for the same single cell. Anal Chem. 2024; 96(14): 5499-5508.

[315] Wang DY, Cao Y, Zheng LY, et al. Target identification of kinase inhibitor alisertib (MLN8237) by using DNA-programmed affinity labeling. Chemistry (Weinheim an der Bergstrasse, Germany). 2017; 23(45): 10906-10914.

[316] Duch W, Swaminathan K, Meller J. Artificial intelligence approaches for rational drug design and discovery. Curr Pharm Design. 2007; 13(14): 1497-1508.

[317] Gupta R, Srivastava D, Sahu M, Tiwari S, Ambasta RK, Kumar P. Artificial intelligence to deep learning: machine intelligence approach for drug discovery. Mol Divers. 2021; 25(3): 1315-1360.

[318] Lu M, Yin J, Zhu Q, et al. Artificial intelligence in pharmaceutical sciences. Engineering. 2023;27:37-69.

[319] Zeng X, Zhu S, Lu W, et al. Target identification among known drugs by deep learning from heterogeneous networks. Chem Sci. 2020; 11(7): 1775-1797.

[320] Wang Y, Liu X, Dong L, et al. iMSEA: a novel metabolite set enrichment analysis strategy to decipher drug interactions. Anal Chem. 2023; 95(15): 6203-6211.

[321] Galal A, Talal M, Moustafa A. Applications of machine learning in metabolomics: disease modeling and classification. Front Genet. 2022; 13: 1017340.

[322] Chen Y, Wang B, Zhao Y, et al. Metabolomic machine learning predictor for diagnosis and prognosis of gastric cancer. Nat Commun. 2024; 15(1): 1657.

[323] Shah HA, Liu J, Yang Z, Zhang X, Feng J. DeepRF: a deep learning method for predicting metabolic pathways in organisms based on annotated genomes. Comput Biol Med. 2022; 147: 105756.

[324] Bonetta Valentino R, Ebejer JP, Valentino G. Machine learning using neural networks for metabolomic pathway analyses. Methods Mol Biol. 2023; 2553: 395-415.

[325] Baranwal M, Magner A, Elvati P, Saldinger J, Violi A, Hero AO. A deep learning architecture for metabolic pathway prediction. Bioinformatics (Oxford, England). 2020; 36(8): 2547-2553.

[326] Shah HA, Liu J, Yang Z, Feng J. Review of machine learning methods for the prediction and reconstruction of metabolic pathways. Front Mol Biosci. 2021; 8: 634141.

[327] Costello Z, Martin HG. A machine learning approach to predict metabolic pathway dynamics from time-series multiomics data. Npj Syst Biol Appl. 2018; 4(1): 1-14.

[328] Mak KK, Pichika MR. Artificial intelligence in drug development: present status and future prospects. Drug Discov Today. 2019; 24(3): 773-780.

[329] Ren F, Aliper A, Chen J, et al. A small-molecule TNIK inhibitor targets fibrosis in preclinical and clinical models. Nat Biotechnol. 2024: 1-13.

[330] Luo R, Sun L, Xia Y, et al. BioGPT: generative pre-trained transformer for biomedical text generation and mining. Brief Bioinform. 2022; 23(6).

[331] Sha Y, Meng W, Luo G, et al. MetDIT: transforming and analyzing clinical metabolomics data with convolutional neural networks. Anal Chem. 2024; 96(7): 2949-2957.

[332] Xu H, Zhao H, Ding C, et al. Celastrol suppresses colorectal cancer via covalent targeting peroxiredoxin 1. Signal Transduct Tar. 2023; 8(1): 51.

[333] Muhammad U, Hoque MZ, Oussalah M, Keskinarkaus A, Seppänen T, Sarder PSAM. Self-augmentation mechanism for COVID-19 detection using chest X-ray images. Knowl-Based Syst. 2022; 241: 108207.

[334] Al-Ssulami AM, Alsorori RS, Azmi AM, Aboalsamh H. Improving coronary heart disease prediction through machine learning and an innovative data augmentation technique. Cogn Comput. 2023; 15(5): 1687-1702.

[335] Chen Y, Xu J, Liu X, Guo L, Yi P, Cheng C. Potential therapies targeting nuclear metabolic regulation in cancer. MedComm. 2023; 4(6): e421.

[336] Pun FW, Ozerov IV, Zhavoronkov A. AI-powered therapeutic target discovery. Trends Pharmacol Sci. 2023; 44(9): 561-572.

[337] Huang Z, Zhang Z, Zhou C, Liu L, Huang C. Epithelial–mesenchymal transition: the history, regulatory mechanism, and cancer therapeutic opportunities. MedComm. 2022; 3(2): e144.

[338] Zhuang Y, Liu K, He Q, Gu X, Jiang C, Wu J. Hypoxia signaling in cancer: implications for therapeutic interventions. MedComm. 2023; 4(1): e203.

RIGHTS & PERMISSIONS

2024 The Author(s). MedComm published by Sichuan International Medical Exchange & Promotion Association (SCIMEA) and John Wiley & Sons Australia, Ltd.